Industry ExaminerSep 17

One shot, two targets. OX40L–TNF bispecifics could reset HS care—if they beat HiSCR benchmarks and keep safety clean. Our FT-style breakdown: biology → data → payer math.
🔗 https://biotech.industryexaminer.com/ox40l-tnf-bispecifics-dermatology-hidradenitis-suppurativa/

#Biotech #HS #Bispecifics #Dermatology

Dermatology’s next play: bispecifics that shut down OX40L and TNF - Biotech Industry Examiner

Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is an audacious idea. A handful of new readouts—plus a quietly advancing early-stage

Biotech Industry Examiner
Show threadYan Leyfman, MDDec 6, 2022
#safety #celltherapy #celltherapies #immunotherapy #genetherapy #cellulartherapeutics #IO #cancer #oncology #dlbcl #lymphoma #cartecells #cartcellrx #nkcells #nkcars #bispecifics #tcellengagers #bloodcancers #lymphoma #multiplemyeloma #solidtumors #Breastcancer #GIcancer #cartcell #cartcells #cartcellrx #msc #mesenchymalstemcells #mesenchymalstemcell #CRISPR #crisprcas9 #genetherapy #geneediting #checkpointinhibitors #bmt #bmtrx #bmtsm #tcellrx